Floatz logo

Atezolizumab

Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.monoclonal_antibodyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Locally Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Exelixis
Phase 1/2CCC
gh21
Suzhou Genhouse Bio Co., Ltd.
Phase 2CCC
Garsorasib
Suzhou Genhouse Bio Co., Ltd.
Phase 2CCC
Pembrolizumab
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2CCC
cvl237 tablets
Convalife (Shanghai) Co., Ltd.
Phase 2CCC

View all 46 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →